The Life Sciences team advised Vigil Neuroscience on its $90 million Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
Vigil is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system.
The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.
The Goodwin team was led by Jacqueline Mercier and Kingsley Taft, Rich Matheny and Gozde Guckaya (Global Trade); Timothy Holahan (Employment) Jacqueline Klosek (Data, Privacy & Cybersecurity); Natasha Dimond (Cap Table); Hayden Hutto (special assistance); and Maggie Wong (Opinion).
For more details, read the press release and articles in Endpoints, Fierce Biotech, and STAT.